What is it? Why is it important?

During study conduct, the rights, safety, and well-being of study participants must remain a primary concern to be guaranteed at all times.

 

During study conduct and participant recruitment:

 

In the event of vulnerable study participants, consent procedures must be adapted and comply with the law (e.g. emergency situations, children, adolescents, adult lacking capacity, pregnant women)

What do I need to do?

As a SP-INV and Site-INV:

 

At participant recruitment:

  • Selection from the target-population must be fair and non-biased (e.g. on vulnerability, privilege or other factors)
  • Inform participants of their study role and duties
  • Know the participant`s rights, that include to:
    • Ensure participants freely decide whether they want to  consent to study participation (i.e. freely sign the Informed Consent Form (ICF))
    • Inform participants about the study (PIS), especially potential study risks (e.g. orally and in writing 
    • Inform participants about conditions related to genetic testing
    • Respect the participant`s wish whether to be informed or not informed about data concerning them
    • Ensure participants know their right to withdraw from the study at any time, without consequences

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ISO 14155:2020 Medical device (access liable to costs) – see in particular sections and annexes

  • 4 GCP summary
  • 5.8 Informed consent
  • 6.2 Risk management
  • 7.4.4 Adverse events risk assessment
  • 9.2.4 Monitoring General
  • Annex B Investigator’s brochure
  • Annex H Application of ISO 14971

SAMS manual “Research with human subjects” – see in particular chapters

  • Chapter 4 Scientific requirements
  • Chapter 5 Selection of study participants
  • Chapter 6 Assessment of risk and benefits
  • Chapter 8 Information and consent
  • Chapter 9 Respect of participants

Swiss Law

HRA – see in particular articles

  • Art. 6 Non discrimination
  • Art. 7 Consent
  • Art. 8 Right to receive information
  • Art. 12 Risks and burdens
  • Art. 16 Informed consent
  • Art. 21-24 Research involving children, adolescents and adults lacking capacity
  • Art. 30-31 Research in Emergency situations
  • Art. 15-17 Clinical Trials in Emergency Situations

ClinO – see in particular articles

  • Art. 7 Information
  • Art. 7a Information in cases of genetic testing
  • Art. 7b Information in cases of prenatal risk assessment
  • Art. 8 Exceptions to written form
  • Art. 9 Consequences of revocation of consent

ClinO-MD – see in particular article

  • Art. 3 Applicable provisions (b,d)

HRO – see in particular articles 

  • Art. 8 Information
  • Art. 8a Information in cases of genetic testing
  • Art. 8b Information in cases of prenatal risk assessment
Abbreviations
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTU – Clinical Trials Unit
  • EC/RA – Ethics Committee / Regulatory Authorities
  • GCP – Good Clinical Practice
  • HRA – Human Research Act
  • HRO – Human Research Ordinance
  • ISO – International Organization for Standardization
  • SAMS – Swiss Academy of Medical Sciences
  • Site-INV – Site Investigator
  • SP-INV – Sponsor Investigator
Conduct ↦ Ethics and Laws ↦ Participant Protection ↦ Requirements
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Ethics and Laws ↦ Participant Protection ↦ Requirements

Please note: the Easy-GCS tool is currently under construction.